logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
C

CPT-Pharmacometrics and Systems Pharmacology

IF3
论文数1071
被引数4051
期刊论文 1071
发表时间
delete
Response to “Enhance Multistate Models With Clinically Meaningful Graphs”对“Enhance Multistate Models With Clinically Meaningful Graphs”的回应
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-09-05
delete0
deleteOAAI
deleteMoustafa M. A. Ibrahim; Maria C. Kjellsson; Mats O. Karlsson
delete分享
delete收藏
Enhance Multistate Models With Clinically Meaningful Graphs增强多状态模型，使用临床上有意义的图形
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-09-05
delete0
deleteOAAI
deleteJoachim Grevel
delete分享
delete收藏
Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy罗苏伐他汀PBPK建模：整合肝脏浓度及种族、基因多态性、内酯形成、药物相互作用和妊娠的影响
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-25
delete0
deleteOAAI
deleteAnkit Balhara; Robert H. Weber; Jashvant D. Unadkat
delete分享
delete收藏
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria基于模型的药物开发在慢性自发性荨麻疹患者中的Ligelizumab应用
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-23
delete0
deleteOAAI
deleteAndrzej Bienczak; Aurelie Gautier; Eva Hua; Yan Ji; Emil Scosyrev; Serge Smeets; Thomas Severin; Anton Drollmann; Manmath Patekar; Marina Savelieva
delete分享
delete收藏
Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients健康受试者和慢性乙型肝炎患者中Pegbing的群体药代动力学模型
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-21
delete0
deleteOAAI
deleteWeizhe Jian; Yalin Yin; Rong Chen; Pingyao Luo; Tianyu Wang; Jianbo Gu; Zhengfang Du; Lei Cai; Tianyu Bao; Junsheng Xue; Ruoyi He; Tianyan Zhou
delete分享
delete收藏
A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules一种联合建模方法用于预测胃排空延迟对小型分子药代动力学的影响
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-21
delete0
deleteOAAI
deleteMaria M. Posada; Karen B. Schneck; Bridget L. Morse; Luc R. A. Rougee; Lai San Tham; Jessica F. Rehmel; Brian Thompson; Stephen D. Stamatis; Stephen D. Hall; Gemma L. Dickinson
delete分享
delete收藏
A Bayesian Approach to Compare Accumulating Survival Data From Clinical Practice With RCT Data: A Case Study in Non-Small Cell Lung Cancer Patients一种贝叶斯方法，用于比较临床实践中累积的生存数据与RCT数据：一项非小细胞肺癌患者的案例分析
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-21
delete0
deleteOAAI
deleteMarjon V. Verschueren; Daniel V. Verschueren; Ewoudt M. W. van de Garde; Lourens T. Bloem
delete分享
delete收藏
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling迈向对Aficamten临床药理学定量理解：群体药代动力学建模
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-17
delete0
deleteOAAI
deleteDonghong Xu; Hanbin Li; Stephen B. Heitner; Daniel L. Jacoby; Stuart Kupfer; Polina German; Justin Lutz
delete分享
delete收藏
Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid TumorsRepotrectinib暴露-反应分析，以支持ROS1阳性NSCLC或NTRK阳性实体瘤患者的剂量推荐
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-17
delete0
deleteOAAI
deleteShengnan Du; Zheyi Hu; Jun Shen; Li Zhu; Amit Roy; Justine Lam; Ming Lu; Anna Kondic; Lora Hamuro
delete分享
delete收藏
Mathematical Modeling of Neuroinflammation in Neurodegenerative Diseases神经退行性疾病中神经炎症的数学建模
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-13
delete0
deleteOAAI
deleteAlex Foster-Powell; Amin Rostami-Hodjegan; Guy Meno-Tetang; Donald E. Mager; Kayode Ogungbenro
delete分享
delete收藏
A Perspective on the Use of Poisson Versus Logistic Regression in Exposure–Response Analysis: Insights and Considerations关于暴露-反应分析中使用泊松回归与逻辑回归的视角：见解与考量
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-12
delete0
deleteOAAI
deleteYiming Cheng; Ping Chen; Yan Li
delete分享
delete收藏
A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC基于厄洛替尼临床数据的晚期NSCLC肿瘤大小模型系统性比较分析
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-11
delete0
deleteOAAI
deleteAnna Mishina; Kirill Zhudenkov; Gabriel Helmlinger; Kirill Peskov
delete分享
delete收藏
Target-Mediated Drug Disposition Revisited: Michaelis–Menten Approximations for Bivalent Drug Molecules靶向介导的药物处置再探讨：双价药物分子的米氏方程近似
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-08
delete0
deleteOAAI
deleteRonny Straube
delete分享
delete收藏
A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3模型指导药物开发的案例研究：一种新型PCSK9反义寡核苷酸。第二部分：从II期到III期
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-05
delete0
deleteOAAI
deleteJane Knöchel; Catarina Nilsson; Björn Carlsson; Alexis Hofherr; Per Johanson; Tina Rydén-Bergsten; Bengt Hamrén; Dinko Rekić
delete分享
delete收藏
Predicting Systemic and Liver Bosentan Exposure Using Physiologically-Based Pharmacokinetic Modeling利用生理药代动力学模型预测全身及肝脏的波生坦暴露情况
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-05
delete0
deleteOAAI
deleteMiao-Chan Huang; Julia Macente; Sofie Heylen; Chen Ning; Kristof De Vos; Neel Deferm; Pieter Annaert
delete分享
delete收藏
A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders基于药代动力学信息指导的试验模拟框架，用于优化罕见神经系统疾病疾病修饰性治疗的研究设计
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-05
delete0
deleteOAAI
deleteYevgen Ryeznik; Ralf-Dieter Hilgers; Nicole Heussen; Emmanuelle Comets; France Mentré; Niels Hendrickx; Mats O. Karlsson; Andrew C. Hooker; Alzahra Hamdan; Xiaomei Chen; Rebecca Schüle; Matthis Synofzik; Oleksandr Sverdlov
delete分享
delete收藏
Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling评估多拉维普酮（Dordaviprone）通过生理药代动力学模型进行细胞色素P450药物相互作用风险分析
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-04
delete0
deleteOAAI
deleteSwati Jaiswal; Nikunjkumar K. Patel; Hannah M. Jones; Savannah McFeely; Shamia L. Faison; Tim Tippin; Odin Naderer
delete分享
delete收藏
Model-Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models基于模型的英夫利昔单抗精准给药在韩国炎症性肠病患者中的应用：群体药代动力学模型的体外验证
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-04
delete0
deleteOAAI
deleteYoonjin Kim; Seung Hwan Baek; In-Jin Jang; Jae-Yong Chung
delete分享
delete收藏
Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients转型儿科罕见病药物研发：利用虚拟患者提升临床试验和监管证据
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-04
delete0
deleteOAAI
deleteFianne Sips; Marco Virgolin; Giuseppe Pasculli; Federico Reali; Alessio Paris; Annette Janus; Yann Godfrin; Daniel Röshammar; Luca Marchetti; Jane Knöchel
delete分享
delete收藏
Moving From Point-Based Analysis to Systems-Based Modeling: Knowledge Integration to Address Antimicrobial Resistance从基于点的分析转向基于系统的建模：知识整合以应对抗生素耐药性
deletecpt pharmacometrics systems pharmacology
IF0
delete2025-08-01
delete0
deleteOAAI
deleteBhavatharini Arun; Gauri G. Rao
delete分享
delete收藏